Sarah Hersey

Sarah Hersey is a seasoned executive in the field of precision medicine, currently serving as Vice President of Precision Medicine at Bristol Myers Squibb since November 2016. Hersey's career includes significant roles at Novartis, where Sarah held the position of Global Head of Future Precision Medicine and was previously Global Head of Nucleic Acid Testing Diagnostic Development. In addition to their work at Bristol Myers Squibb, Hersey is active on several boards, including serving as a Board Observer for Precede Biosciences, Board Member for the Personalized Medicine Coalition, and Independent Board Member for Sampled. Hersey's academic background includes a Master of Science in Biology (Biochemistry) and multiple degrees in Chemistry and Biology from Northern Illinois University, complemented by an MBA from California State University-Dominguez Hills.